Jasper Therapeutics, Inc. SEC filings

Filings

Every filing, newest first. MAJOR and NOTABLE filings lead the app's feed; ROUTINE ones are kept here.

1. ROUTINE8-KJasper Therapeutics, Inc.JSPRW4d

   Jasper Therapeutics completes IgAN cohort enrollment

   • Completed enrollment of IgA nephropathy cohort
   • Phase 2 basket study for vensobafusp alfa
   • Press release filed as Exhibit 99.1
2. ROUTINES-3Jasper Therapeutics, Inc.JSPRW4d

   Jasper Therapeutics files S-3

   • Filed Form S-3 on 2026-10-14
   • Up to 284,013,011 shares of common stock
   • Resale of 4,655,951 preferred shares
3. ROUTINEPRE 14AJasper Therapeutics, Inc.JSPRWOct 9

   Jasper Therapeutics to hold virtual meeting

   • Filed PRE 14A on 2026-10-09
   • Special meeting on Nov [__], 2026
   • Votes needed for four proposals
4. ROUTINESC TO-IJasper Therapeutics, Inc.JSPRWOct 8

   Jasper Therapeutics offers to buy warrants

   • Warrants exercisable at $2.92 per share
   • Offer price of $0.324 per warrant
   • Expiration date: November 6, 2026
5. ROUTINE8-KJasper Therapeutics, Inc.JSPRWOct 8

   Jasper Therapeutics offers to buy back warrants

   • Offer price: $0.324 per warrant
   • 12,345,707 warrants outstanding as of Oct 6, 2026
   • Offer ends Nov 6, 2026
6. ROUTINE8-KJasper Therapeutics, Inc.JSPRWOct 5

   Jasper Therapeutics approves stock split

   • 21,747,865 shares represented at meeting
   • Reverse stock split ratio 1-for-15 to 1-for-35
   • Authorized shares increased to 675M
7. ROUTINE8-K/AJasper Therapeutics, Inc.JSPRWOct 5

   Jasper Therapeutics acquires Kira Pharmaceuticals

   • Completed acquisition of Kira Pharmaceuticals on July 16, 2026
   • Issued 5,195,009 shares of Common Stock and 4,644,977 shares of Preferred Stock
   • Entered into a $132.0 million financing deal
8. ROUTINE8-K/AJasper Therapeutics, Inc.JSPRWOct 1

   Current report (amended)

9. ROUTINE8-KJasper Therapeutics, Inc.JSPRWSep 28

   Current report

10. NOTABLE25-NSEJasper Therapeutics, Inc.JSPRWSep 24

    Delisting notice

    Nasdaq Stock Market LLC, filed by

11. ROUTINEDEF 14AJasper Therapeutics, Inc.JSPRWSep 4

    Proxy statement

12. ROUTINE8-KJasper Therapeutics, Inc.JSPRWAug 26

    Current report

13. ROUTINEPRE 14AJasper Therapeutics, Inc.JSPRWAug 24

    Preliminary proxy statement

14. ROUTINESCHEDULE 13GJasper Therapeutics, Inc.JSPRWAug 17

    Ownership stake disclosure by Velan Capital Investment Management LP

    Velan Capital Investment Management LP, filed by

15. ROUTINE8-KJasper Therapeutics, Inc.JSPRWAug 14

    Current report

16. NOTABLE10-QJasper Therapeutics, Inc.JSPRWAug 14

    Quarterly report

17. ROUTINE4Jasper Therapeutics, Inc.JSPRWAug 4

    5 insider filings

    Svetlana Lucas, insider filing for JSPRW

    Show all 5

    • 4Insider filing for JSPRWAug 4
    • 4Insider filing for JSPRWAug 4
    • 4Insider filing for JSPRWAug 4
    • 4Insider filing for JSPRWAug 4
    • 4Insider filing for JSPRWAug 4

    Svetlana Lucas, reporting

18. ROUTINE8-KJasper Therapeutics, Inc.JSPRWAug 3

    Current report

19. ROUTINE8-KJasper Therapeutics, Inc.JSPRWJul 31

    Current report

20. ROUTINE3Jasper Therapeutics, Inc.JSPRWJul 23

    Greg Keenan, new insider at JSPRW

    Greg Keenan, reporting

21. ROUTINE4Jasper Therapeutics, Inc.JSPRWJul 22

    3 insider filings

    Matthew E Ros, insider filing for JSPRW

    Show all 3

    • 4Insider filing for JSPRWJul 22
    • 3New insider at JSPRWJul 22
    • 3New insider at JSPRWJul 22

    Matthew E Ros, reporting

22. ROUTINE4Jasper Therapeutics, Inc.JSPRWJul 20

    2 insider filings

    Patrick J Crutcher, insider filing for JSPRW

    Show all 2

    • 4Insider filing for JSPRWJul 20
    • 3New insider at JSPRWJul 20

    Patrick J Crutcher, reporting

23. NOTABLESCHEDULE 13D/AJasper Therapeutics, Inc.JSPRWJul 20

    Ownership stake disclosure by Velan Capital Investment Management LP (amended)

    Velan Capital Investment Management LP, filed by

24. ROUTINE8-KJasper Therapeutics, Inc.JSPRWJul 17

    Current report

25. ROUTINE8-KJasper Therapeutics, Inc.JSPRWJul 16

    Current report

26. ROUTINESCHEDULE 13G/AJasper Therapeutics, Inc.JSPRWJul 10

    Ownership stake disclosure by INTEGRATED CORE STRATEGIES (US) LLC (amended)

    INTEGRATED CORE STRATEGIES (US) LLC, filed by

27. ROUTINEARSJasper Therapeutics, Inc.JSPRWJun 15

    Annual report to shareholders

28. ROUTINEDEFA14AJasper Therapeutics, Inc.JSPRWJun 15

    Additional proxy materials

29. ROUTINEDEF 14AJasper Therapeutics, Inc.JSPRWJun 15

    Proxy statement

30. ROUTINE8-KJasper Therapeutics, Inc.JSPRWJun 9

    Current report

31. ROUTINE8-KJasper Therapeutics, Inc.JSPRWJun 1

    Current report

32. ROUTINE8-KJasper Therapeutics, Inc.JSPRWMay 21

    Current report

33. NOTABLE10-QJasper Therapeutics, Inc.JSPRWMay 14

    Quarterly report

34. ROUTINE8-KJasper Therapeutics, Inc.JSPRWMay 14

    Current report

35. ROUTINESCHEDULE 13G/AJasper Therapeutics, Inc.JSPRWMay 12

    Ownership stake disclosure by Stanley Morgan (amended)

    Stanley Morgan, filed by

36. ROUTINESCHEDULE 13G/AJasper Therapeutics, Inc.JSPRWMay 8

    Ownership stake disclosure by Soleus Capital Master Fund, L.P. (amended)

    Soleus Capital Master Fund, L.P., filed by

37. ROUTINESCHEDULE 13G/AJasper Therapeutics, Inc.JSPRWMay 8

    Ownership stake disclosure by GOLDMAN SACHS GROUP INC (amended)

    GOLDMAN SACHS GROUP INC, filed by

38. ROUTINE10-K/AJasper Therapeutics, Inc.JSPRWApr 30

    Annual report (amended)

39. ROUTINE8-KJasper Therapeutics, Inc.JSPRWMar 30

    Current report

40. NOTABLE10-KJasper Therapeutics, Inc.JSPRWMar 30

    Annual report

41. ROUTINESCHEDULE 13GJasper Therapeutics, Inc.JSPRWFeb 25

    Ownership stake disclosure by INTEGRATED CORE STRATEGIES (US) LLC

    INTEGRATED CORE STRATEGIES (US) LLC, filed by

42. NOTABLESCHEDULE 13D/AJasper Therapeutics, Inc.JSPRWFeb 18

    Ownership stake disclosure by Carlyle Group Inc. (amended)

    Carlyle Group Inc., filed by

43. ROUTINESCHEDULE 13GJasper Therapeutics, Inc.JSPRWFeb 12

    Ownership stake disclosure by GOLDMAN SACHS GROUP INC

    GOLDMAN SACHS GROUP INC, filed by

Older filings on EDGAR